# 601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO)

> **NCT04667910** · PHASE2 · COMPLETED · sponsor: **Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.** · enrollment: 60 (actual)

## Conditions studied

- Central Retinal Vein Occlusion

## Interventions

- **DRUG:** 601 1.25mg
- **DRUG:** Ranibizuman 0.5 mg

## Key facts

- **NCT ID:** NCT04667910
- **Lead sponsor:** Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-27
- **Primary completion:** 2022-11-16
- **Final completion:** 2022-11-16
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04667910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04667910, "601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04667910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*